publication date: Nov. 8, 2019

Conversation with The Cancer Letter

Purdue’s Thompson: Lomustine establishes proof of principle for resolving cancer drug shortages

David Thompson 

David H. Thompson

Professor, Department of Chemistry, Purdue University

Member, Purdue Center for Cancer Research

 

David H. Thompson, a professor at the Department of Chemistry at Purdue University and a member of the Purdue Center for Cancer Research, is working on a better and faster way to produce drugs and eliminate shortages.

Using an approach called continuous manufacturing, his lab can now produce a sufficient quantity of the cancer drug lomustine to meet all of the U.S. needs.

For now, this can be accomplished with machinery that takes up about as much space as a small refrigerator.

Though several drugs in the U.S. are produced partially using continuous manufacturing, none are synthesized from start to finish with this method. Thompson, whose work is funded by DARPA, wants to receive FDA approval for making a generic version of lomustine.

He believes that current capabilities of this technology make it possible to produce four of the six cancer drugs on the FDA shortage list.

They are: dexamethasone, dexrazoxane, leucovorin, and methotrexate. Two other drugs—vinblastin and vincristine—are beyond current total synthesis capabilities.

 

Thompson spoke with Paul Goldberg, editor and publisher of The Cancer Letter.

 

Paul Goldberg:

I’m puzzled by this entire issue of drug shortages. Every two years, … Continue reading Purdue’s Thompson: Lomustine establishes proof of principle for resolving cancer drug shortages

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.